We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Shire started looking for a buyer for a small biologics manufacturing site in Massachusetts shortly after its buyout of Baxalta two years ago. It has finally made a deal.
China has eased its drug regulations in hopes of drawing some of the new meds for which its citizens are clamoring. Swiss CDMO Lonza is joining a rush of companies looking to cash in on the situation by establishing its firs.
The joint venture combines the strong biologics development pipeline of Sanofi with the expertise of Lonza to design, construct, start-up and operate a state-of-the-art large-scale mammalian cell culture facility